Cisplatin-induced senescence and growth inhibition in human non-small cell lung cancer cells with ectopic transfer of p16INK4a

Oncology Research

Volumn 16, Issue 10, 2007, Pages 479-488

  Fang, Kang ^a   Chiu, Chien Chih ^a,b   Li, Chin Hsiao ^a   Chang, Yung Ta ^a   Hwang, Hwei Tein ^a  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cisplatin; Human non small cell lung cancer cells; p16INK4a

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL AGING; CELL BASED GENE THERAPY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENE TRANSFER; GENETIC CODE; GENETIC TRANSFECTION; LUNG NON SMALL CELL CANCER; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 38149024065     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504007783338331     Document Type: Article

References (39)

1. Landis, S. H.; Murray, T.; Bolden, S.; Wingo, P. A. Cancer statistics, 1999. CA: A Cancer Journal for Clinicians 49:8-31; 1999.
2. Androulakis, N.; Georgoulias, V. NSCLC - platinum or not. Lung Cancer 47:381-383; 2005.
3. Siddik, Z. H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279; 2003.
4. Ohe, Y. Chemoradiotherapy for lung cancer. Exp. Opin. Pharmacother. 6:2793-2804; 2005.
5. Seve, P.; Dumontet, C. Chemoresistance in non-small cell lung cancer. Curr. Med. Chem. Anticancer Agents 5:73-88; 2005.
6. Chai, J.; Charboneau, A. L.; Betz, B. L.; Weissman, B. E. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res. 65:10192-10198; 2005.
7. Campling, B. G.; El-Deiry, W. S. Clinical implication of p53 mutation in lung cancer. Mol. Biotechnol. 24:141-156; 2003.
8. Chkhotua, A. B.; Gabusi, E.; Altimari, A.; D'Errico, A.; Yakubovich, M.; Vienken, J.; Stefoni, S.; Chieco, P.; Yussim, A.; Grigioni, W. F. Increased expression of p16(INK4a) and p27(Kip1) cyclin-dependent kinase inhibitor genes in aging human kidney and chronic allograft nephropathy. Am. J. Kidney Dis. 41:1303-1313; 2003.
9. Swanton, C. Cell-cycle targeted therapies. Lancet Oncol. 5:27-36; 2004.
10. Shapiro, G. I.; Edwards, C. D.; Ewen, M. E.; Rollins, B. J. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol. Cell. Biol. 18:378-387; 1998.
11. Tsutsui, T.; Kumakura, S-i.; Yamamoto, A.; Kanai, H.; Tamura, Y.; Kato, T.; Anpo, M.; Tahara, H.; Barrett, J. C. Association of p16INK4a and pRb inactivation with immortalization of human cells. Carcinogenesis 23:2111-2117; 2002.
12. Bodner-Adle, B.; Bodner, K.; Czerwenka, K.; Kimberger, O.; Leodolter, S.; Mayerhofer, K. Expression of p16 protein in patients with uterine smooth muscle tumors: An immunohistochemical analysis. Gynecol. Oncol. 96:62-66; 2005.
13. Singh, M.; Parnes, M. B.; Spoelstra, N.; Bleile, M. J.; Robinson, W. A. p16 expression in sentinel nodes with metastatic breast carcinoma: Evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis. Hum. Pathol. 35:1524-1530; 2004.
14. Beausejour, C. M.; Krtolica, A.; Galimi, F.; Narita, M.; Lowe, S. W.; Yaswen, P.; Campisi, J. Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J. 22:4212-4222; 2003.
15. Sviderskaya, E. V.; Hill, S. P.; Evans-Whipp, T. J.; Chin, L.; Orlow, S. J.; Easty, D. J.; Cheong, S. C.; Beach, D.; DePinho, R. A.; Bennett, D. C. p16Ink4a in melanocyte senescence and differentiation. J. Natl. Cancer Inst. 94: 446-454; 2002.
16. Kim, J. H.; Lee, G. E.; Kim, S. W.; Chung, I. K. Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells. Biochem. J. 373:523-529; 2003.
17. Dimri, G. P.; Lee, X.; Basile, G.; Acosta, M.; Scott, G.; Roskelley, C.; Medrano, E. E.; Linskens, M.; Rubelj, I.; Pereira-Smith, O. A.; Peacocke, M.; Campisi, J. Biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92: 9363-9367; 1995.
18. Roninson, I. B. Tumor cell senescence in cancer treatment. Cancer Res. 63:2705-2715; 2003.
19. Bond, J.; Jones, C.; Haughton, M.; DeMicco, C.; Kipling, D.; Wynford-Thomas, D. Direct evidence from siRNA-directed "knock down" that p16(INK4a) is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation. Exp. Cell Res. 292:151-156; 2004.
20. Shay, J. W.; Roninson, I. B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23:2919-2933; 2004.
21. Saretzki, G. Telomerase inhibition as cancer therapy. Cancer Lett. 194:209-219; 2003.
22. Sharpless, N. E. Ink4a/Arf links senescence and aging. Exp. Gerontol. 39:1751-1759; 2004.
23. Hirose, Y.; Berger, M. S.; Pieper, R. O. Abrogation of the Chk1-mediated G.2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 61:5843-5849; 2001.
24. Noda, A.; Ning, Y.; Venable, S. F.; Pereira-Smith, O. M.; Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211:90-98; 1994.
25. Castellano, M.; Gabrielli, B. G.; Hussussian, C. J.; Dracopoli, N. C.; Hayward, N. K. Restoration of Cdk N2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J. Invest. Dermatol. 109:61-68; 1997.
26. Gabrielli, B. G.; Clark, J. M.; McCormack, A. K.; Ellem, K. A. Ultraviolet light-induced G2 phase cell cycle checkpoint blocks cdc25-dependent progression into mitosis. Oncogene 15:749-758; 1997.
27. Fang, L.; Igarashi, M.; Leung, J.; Sugrue, M. M.; Lee, S. W.; Aaronson, S. A. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18:2789-2797; 1999.
28. Duan, J.; Chen, Z.; Liu, P.; Zhang, Z.; Tong, T. Wild-type p16INK4a suppresses cell growth, telomerase activity and DNA repair in human breast cancer MCF-7 cells. Int. J. Oncol. 24:1597-1605; 2004.
29. Lee, A. W.; Li, J. H.; Shi, W.; Li, A.; Ng, E.; Liu, T. J.; Klamut, H. J.; Liu, F. F. p16 gene therapy: A potentially efficacious modality for nasopharyngeal carcinoma. Mol. Cancer Ther. 2:961-969; 2003.
30. Kim, S. K.; Wang, K. C.; Cho, B. K.; Lim, S. Y.; Kim, Y. Y.; Oh, C. W.; Chung, Y. N.; Kim, C. Y.; Lee, C. T.; Kim, H. J. Adenoviral p16/CDKN2 gene transfer to malignant glioma: Role of p16 in growth, invasion, and senescence. Oncol. Rep. 10:1121-1126; 2003.
31. Strauss, B. E.; Fontes, R. B.; Lotfi, C. F.; Skorupa, A.; Bartol, I.; Cipolla-Neto, J.; Costanzi-Strauss, E. Retroviral transfer of the p16INK4a cDNA inhibits C6 glioma formation in Wistar rats. Cancer Cell Int. 2:2; 2002.
32. Lee, Y. H.; Lin, C. H.; Hsu, L. W.; Hu, S. Y.; Hsiao, W. T.; Ho, Y. S. Roles of ionotropic glutamate receptors in early developing neurons derived from the P19 mouse cell line. J. Biomed. Sci. 10:199-207; 2003.
33. Rhee, J. G.; Li, D.; O'Malley, Jr., B. W.; Suntharalingam, M. Combination radiation and adenovirus-mediated P16(INK4A) gene therapy in a murine model for head and neck cancer. ORL J. Otorhinolaryngol. Relat. Spec. 65: 144-154; 2003.
34. Kamb, A.; Gruis, N. A.; Weaver-Feldhaus, J.; Liu, Q.; Harshman, K.; Tavtigian, S. V.; Stockert, E.; Day, R. S.; Johnson, B. E.; Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440; 1994.
35. Itahana, K.; Dimri, G.; Campisi, J. Regulation of cellular senescence by p53. Eur. J. Biochem. 268:2784-2791; 2001.
36. Grim, J.; D'Amico, A.; Frizelle, S.; Zhou, J.; Kratzke, R. A.; Curiel, D. T. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. Clin. Cancer Res. 3:2415-2423; 1997.
37. Pavey, S.; Russell, T.; Gabrielli, B. G2 phase cell cycle arrest in human skin following UV irradiation. Oncogene 20:6103-6110; 2001.
38. Alcorta, D.; Xiong, Y.; Phelps, D.; Hannon, G.; Beach, D.; Barrett, J. A. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA 93: 13742-13747; 1996.
39. Robles, S. J.; Adami, G. R. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 16: 1113-1123; 1998.